TY - JOUR
T1 - Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
AU - An, Zesheng
AU - Figueroa-Parra, Gabriel
AU - Zhou, Xian
AU - Li, Yanfeng
AU - Jaquith, Jane
AU - McCarthy-Fruin, Kathleen
AU - Sletten, Jennifer
AU - Warrington, Kenneth J.
AU - Weyand, Cornelia
AU - Crowson, Cynthia S.
AU - Chumsri, Saranya
AU - Knutson, Keith L.
AU - Sanchez-Rodriguez, Alain
AU - Thanarajasingam, Uma
AU - Duarte-García, Alí
AU - Zeng, Hu
N1 - Publisher Copyright:
Copyright © 2023 An, Figueroa-Parra, Zhou, Li, Jaquith, McCarthy-Fruin, Sletten, Warrington, Weyand, Crowson, Chumsri, Knutson, Sanchez-Rodriguez, Thanarajasingam, Duarte-García and Zeng.
PY - 2023
Y1 - 2023
N2 - Introduction: The longitudinal responses towards multiple doses of COVID-19 mRNA vaccines in patients with systemic autoimmune diseases remain incompletely understood. While observational studies suggested the safety of COVID-19 mRNA vaccines in rheumatic disease patients, laboratory evidence is lacking. Methods: Here we evaluated seroreactivity, clinical manifestions, and multiple disease biomarkers after 2 or 3 doses of COVID-19 mRNA vaccines in a cohort of patients with rheumatic diseases. Results: Most patients generated high SARS-CoV-2 spike-specific neutralizing antibodies comparable to those in healthy controls after 2 doses of mRNA vaccines. The antibody level declined over time but recovered after the third dose of the vaccine. Patients with systemic lupus erythematosus (SLE) or psoriatic arthritis (PsA) remained without significant flares post-vaccination. The changes in anti-dsDNA antibody concentration and expression of type I interferon (IFN) signature genes were highly variable but did not show consistent or significant increases. Frequency of double negative 2 (DN2) B cells remained largely stable. Discussion: Our data provide experimental evidences indicating the efficacy and safety of repeated COVID-19 mRNA vaccination in rheumatic disease patients.
AB - Introduction: The longitudinal responses towards multiple doses of COVID-19 mRNA vaccines in patients with systemic autoimmune diseases remain incompletely understood. While observational studies suggested the safety of COVID-19 mRNA vaccines in rheumatic disease patients, laboratory evidence is lacking. Methods: Here we evaluated seroreactivity, clinical manifestions, and multiple disease biomarkers after 2 or 3 doses of COVID-19 mRNA vaccines in a cohort of patients with rheumatic diseases. Results: Most patients generated high SARS-CoV-2 spike-specific neutralizing antibodies comparable to those in healthy controls after 2 doses of mRNA vaccines. The antibody level declined over time but recovered after the third dose of the vaccine. Patients with systemic lupus erythematosus (SLE) or psoriatic arthritis (PsA) remained without significant flares post-vaccination. The changes in anti-dsDNA antibody concentration and expression of type I interferon (IFN) signature genes were highly variable but did not show consistent or significant increases. Frequency of double negative 2 (DN2) B cells remained largely stable. Discussion: Our data provide experimental evidences indicating the efficacy and safety of repeated COVID-19 mRNA vaccination in rheumatic disease patients.
KW - COVID-19 mRNA vaccine
KW - SARS-CoV-2
KW - Sjögren’s syndrome
KW - psoriatic arthritis
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85168062122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168062122&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1224702
DO - 10.3389/fimmu.2023.1224702
M3 - Article
C2 - 37583697
AN - SCOPUS:85168062122
SN - 1664-3224
VL - 14
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1224702
ER -